DE602004019919D1 - Modulation der wechselwirkung zwischen hgf-beta-kette und c-met - Google Patents

Modulation der wechselwirkung zwischen hgf-beta-kette und c-met

Info

Publication number
DE602004019919D1
DE602004019919D1 DE602004019919T DE602004019919T DE602004019919D1 DE 602004019919 D1 DE602004019919 D1 DE 602004019919D1 DE 602004019919 T DE602004019919 T DE 602004019919T DE 602004019919 T DE602004019919 T DE 602004019919T DE 602004019919 D1 DE602004019919 D1 DE 602004019919D1
Authority
DE
Germany
Prior art keywords
met
modulation
interaction
beta chain
hgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004019919T
Other languages
English (en)
Inventor
Daniel K Kirchhofer
Robert A Lazarus
Xiaoyi Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004019919(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE602004019919D1 publication Critical patent/DE602004019919D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
DE602004019919T 2003-06-06 2004-06-04 Modulation der wechselwirkung zwischen hgf-beta-kette und c-met Active DE602004019919D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47677803P 2003-06-06 2003-06-06
US53211703P 2003-12-23 2003-12-23
PCT/US2004/017901 WO2005001486A1 (en) 2003-06-06 2004-06-04 Modulating the interaction between hgf beta chain and c-met

Publications (1)

Publication Number Publication Date
DE602004019919D1 true DE602004019919D1 (de) 2009-04-23

Family

ID=33555430

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004019919T Active DE602004019919D1 (de) 2003-06-06 2004-06-04 Modulation der wechselwirkung zwischen hgf-beta-kette und c-met

Country Status (17)

Country Link
US (8) US20060035278A9 (de)
EP (3) EP2367008A3 (de)
JP (1) JP2007526447A (de)
KR (2) KR101148657B1 (de)
AT (1) ATE425463T1 (de)
AU (1) AU2004252475A1 (de)
CA (1) CA2528343A1 (de)
DE (1) DE602004019919D1 (de)
DK (1) DK1636593T5 (de)
ES (1) ES2323425T3 (de)
HK (1) HK1092872A1 (de)
HR (1) HRP20090324T1 (de)
MX (1) MXPA05013181A (de)
PL (1) PL1636593T3 (de)
PT (1) PT1636593E (de)
SI (1) SI1636593T1 (de)
WO (1) WO2005001486A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
TW201319088A (zh) * 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
JP2008516629A (ja) 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
SI1846406T1 (sl) 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
CN101180410A (zh) * 2005-03-25 2008-05-14 健泰科生物技术公司 肺癌中的c-met突变
ES2539790T3 (es) * 2005-03-25 2015-07-06 Genentech, Inc. Métodos y composiciones para modular c-met hiperestabilizado
KR101259655B1 (ko) * 2005-04-15 2013-04-30 제넨테크, 인크. Ｈｇｆ 베타 사슬 변이체
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
MX2009006779A (es) 2006-12-19 2009-08-27 Genentech Inc Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
JP5490688B2 (ja) 2007-06-22 2014-05-14 アークル インコーポレイテッド 癌の治療のためのインドリルピロリジン
WO2009002808A2 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
EP2219656A2 (de) 2007-11-09 2010-08-25 New York Medical College Verfahren zur reparatur und/oder regeneration von geschädigtem myokard mit varianten des hepatozyten-wachstumsfaktors
EP2257293A2 (de) * 2008-03-06 2010-12-08 Genentech, Inc. Kombinationstherapie mit c-met- und egfr-antagonisten
US9157920B2 (en) * 2009-06-26 2015-10-13 Peas Institut Ab Method for determining biologically active HGF
JP5814925B2 (ja) 2009-10-22 2015-11-17 ジェネンテック， インコーポレイテッド 抗ヘプシン抗体及びその使用方法
EP3511342B1 (de) 2010-03-10 2024-01-17 Genmab A/S Monoklonale antikörper gegen c-met
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013143376A1 (zh) 2012-03-26 2013-10-03 武汉盛云生物医药科技有限责任公司 含1，2，4-三嗪-3，5-二酮的喹啉类化合物及其应用
LT2839860T (lt) 2012-10-12 2019-07-10 Medimmune Limited Pirolobenzodiazepinai ir jų konjugatai
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3270918A4 (de) 2015-03-16 2018-10-24 Celldex Therapeutics, Inc. Anti-met-antikörper und verfahren zur verwendung davon
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
JP7380999B2 (ja) * 2018-09-06 2023-11-15 国立大学法人 東京大学 環状ペプチド
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0739904A1 (de) 1989-06-29 1996-10-30 Medarex, Inc. Bispezifische Reagenzien für die AIDS-Therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
ATE155525T1 (de) * 1991-05-10 1997-08-15 Pharmacia & Upjohn Spa Verkürzte formen den hepatozyten wachstumsfaktor (hgf) rezeptors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
ATE195652T1 (de) 1992-12-02 2000-09-15 Alkermes Inc Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
EP0779806B2 (de) 1994-09-09 2008-04-16 Takeda Pharmaceutical Company Limited Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5647409A (en) 1995-04-04 1997-07-15 Allergan On-site syringe filling apparatus for viscoelastic materials, and corresponding method for on-site syringe filling
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
CZ288147B6 (en) 1995-06-07 2001-05-16 Alkermes Inc Preparation for prolonged release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US5911252A (en) 1997-04-29 1999-06-15 Cassel; Douglas Automated syringe filling system for radiographic contrast agents and other injectable substances
US6677377B2 (en) * 2000-06-21 2004-01-13 Georgetown University School Of Medicine Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions

Also Published As

Publication number Publication date
PT1636593E (pt) 2009-06-03
US20130143813A1 (en) 2013-06-06
KR20060017634A (ko) 2006-02-24
DK1636593T5 (da) 2009-07-27
HK1092872A1 (en) 2007-02-16
JP2007526447A (ja) 2007-09-13
EP2093570A1 (de) 2009-08-26
CA2528343A1 (en) 2005-01-06
EP1636593A1 (de) 2006-03-22
KR101148657B1 (ko) 2012-07-05
EP1636593B9 (de) 2009-12-16
PL1636593T3 (pl) 2009-08-31
US20190054138A1 (en) 2019-02-21
ATE425463T1 (de) 2009-03-15
EP2367008A3 (de) 2014-12-24
US20070129301A1 (en) 2007-06-07
AU2004252475A1 (en) 2005-01-06
US20050037431A1 (en) 2005-02-17
US20110177058A1 (en) 2011-07-21
SI1636593T1 (sl) 2009-08-31
US20170106042A1 (en) 2017-04-20
HRP20090324T1 (hr) 2010-02-28
EP1636593B1 (de) 2009-03-11
DK1636593T3 (da) 2009-06-15
US20060035278A9 (en) 2006-02-16
WO2005001486A1 (en) 2005-01-06
ES2323425T3 (es) 2009-07-15
MXPA05013181A (es) 2006-06-23
US20150126448A1 (en) 2015-05-07
EP2367008A2 (de) 2011-09-21
KR20110117728A (ko) 2011-10-27
US20100040634A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
ATE425463T1 (de) Modulation der wechselwirkung zwischen hgf-beta- kette und c-met
DK1644336T3 (da) Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
NO20075412L (no) Fremgangsmater og preparater til modulering av hyperstabilisert C-MET
ATE411290T1 (de) Allosterische modulatoren von metabotropen glutamatrezeptoren
ATE512222T1 (de) Modulation der expression von diacylglycerin- acyltransferase 2
ATE492526T1 (de) Retinoid derivate mit antiangiogener, antitumor und proapoptotischer wirkung
HK1101178A1 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ES2193389T3 (es) Fenilcetoenoles 2-y 2,5-substituidos.
BR0003184A (pt) Métodos para tratamento de pigmentação da pele
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60223923D1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
BRPI0515670A (pt) anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met
ATE460923T1 (de) Lyophilisierung von virosomen
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
ATE519845T1 (de) Modulation der glucagonrezeptorexpression
CY1111750T1 (el) Νευροτροφικοι παραγοντες
HK1133394A1 (en) Method to enhance tissue regeneration
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE400273T1 (de) 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)- ethylcyclohexanol-derivate als monoamin- wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen
ATE251851T1 (de) Verwendung von schwefel-organischen verbindungen als mittel zur bathochromen verschiebung der uv/vis-absorptionsbande von carotinoiden
ATE403665T1 (de) Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1
DE60237756D1 (de) Zusammensetzungen zur verhinderung der thrombozytenaggregation
DE60213522D1 (de) Kombination von Arnica, Ruscus und Menthol

Legal Events

Date Code Title Description
8363 Opposition against the patent